$211 Million is the total value of Prosight Management, LP's 41 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PSNL | Exit | PERSONALIS INC | $0 | – | -58,668 | -100.0% | -0.06% | – |
| Exit | TENAYA THERAPEUTICS INC | $0 | – | -107,063 | -100.0% | -0.12% | – | |
| EOLS | Exit | EVOLUS INC | $0 | – | -66,438 | -100.0% | -0.27% | – |
| GOSS | Exit | GOSSAMER BIO INC | $0 | – | -265,000 | -100.0% | -0.31% | – |
| RCKT | Exit | ROCKET PHARMACEUTICALS INC | $0 | – | -32,193 | -100.0% | -0.34% | – |
| BMEA | Exit | BIOMEA FUSION INC | $0 | – | -81,907 | -100.0% | -0.38% | – |
| Exit | CASSAVA SCIENCES INCput | $0 | – | -40,900 | -100.0% | -0.66% | – | |
| Exit | SEAGEN INCcall | $0 | – | -12,000 | -100.0% | -0.84% | – | |
| OSH | Exit | OAK STR HEALTH INC | $0 | – | -84,000 | -100.0% | -0.98% | – |
| CSII | Exit | CARDIOVASCULAR SYS INC DEL | $0 | – | -145,916 | -100.0% | -1.08% | – |
| NTLA | Exit | INTELLIA THERAPEUTICS INC | $0 | – | -72,116 | -100.0% | -1.37% | – |
| HCAT | Exit | HEALTH CATALYST INC | $0 | – | -347,724 | -100.0% | -2.02% | – |
| TNET | Exit | TRINET GROUP INC | $0 | – | -78,000 | -100.0% | -2.88% | – |
| ALBO | Exit | ALBIREO PHARMA INC | $0 | – | -486,726 | -100.0% | -5.74% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.